Biogen 2Q Revenues: $2.9 billion (+12%) 2Q Earnings: $1.1 billion (+13%) Comments: Growth in the quarter was driven by the multiple sclerosis and hemophilia businesses. TECFIDERA sales were up 12% to $987 million. AVONEX sales were down 2% to $606 million, while PLEGRIDY sales were up 65% to $123 million. TYSABRI sales were $497 million, up 7%. ELOCTATE and ALPROLIX sales were $125 million, up 68%, and $80 million, up 48%, respectively....